Observational studyFrontiers in endocrinology2026
Dapagliflozin and linagliptin combination therapy improves time in range and reverses hepatic steatosis in patients with type 2 diabetes and hypertension.
Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes mellitus (T2DM) with comorbid hypertension increases risks of vascular complications, necessitating optimized therapies. This study evaluated whether dapagliflozin combined with linagliptin improves time in range (TIR) and hepatorenal function compared to monotherapy in this population. Methods: In this prospective observational cohort study at Danzhou People's Hospital (June 2021-September 2024), 136 patients aged 40-70 years with T2DM (HbA1c 7.5-11.0%) and hypertension were allocated to four groups (n=34 each): standard care (control), dapagliflozin (10 mg/day), linagliptin (5 mg/day), or combination therapy. Outcomes after 12 weeks included TIR via continuous glucose monitoring, blood pressure, lipids, hepatic (ALT, AST, liver-to-spleen ratio via CT), and renal parameters (UACR, eGFR). Data were analyzed using ANOVA, correlations, and regression. Results: Combination therapy achieved superior TIR (94.86 ± 3.65% vs. ~80% in monotherapies and 81.44% in control; P<0.001), with greater reductions in HbA1c (to 5.52%), fasting glucose, blood pressure (systolic to 124 mmHg), lipids (triglycerides to 0.72 mmol/L), liver enzymes (ALT to 9.74 U/L), and UACR (to 7.36 mg/g), plus higher eGFR (to 122.41 mL/min/1.73m²; all P<0.05 vs. others). TIR correlated with improved hepatorenal markers; combination therapy predicted greatest TIR change (β=7.896, P<0.001). Conclusion: Dapagliflozin-linagliptin combination offers superior glycemic stability and organ protection, supporting its use for managing T2DM with hypertension.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.